During the last session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s traded shares were 0.6 million, with the beta value of the company hitting 1.64. At the end of the trading day, the stock’s price was $8.42, reflecting an intraday loss of -5.61% or -$0.5. The 52-week high for the EYPT share is $13.98, that puts it down -66.03 from that peak though still a striking 53.56% gain since the share price plummeted to a 52-week low of $3.91. The company’s market capitalization is $579.39M, and the average trade volume was 827.66K shares over the past three months.
EyePoint Pharmaceuticals Inc (EYPT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.08. EYPT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.82.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
EyePoint Pharmaceuticals Inc (EYPT) registered a -5.61% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.61% in intraday trading to $8.42, hitting a weekly high. The stock’s 5-day price performance is -4.97%, and it has moved by 35.59% in 30 days. Based on these gigs, the overall price performance for the year is -6.55%.
The consensus price target of analysts on Wall Street is $26, which implies an increase of 67.62% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $22 and $30 respectively. As a result, EYPT is trading at a discount of -256.29% off the target high and -161.28% off the low.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
In the rating firms’ projections, revenue will decrease -8.18% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.82M as predicted by 12 analyst(s). Meanwhile, a consensus of 12 analyst(s) estimates revenue growth to 7.85M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 9.48M and 10.52M respectively. In this case, analysts expect current quarter sales to shrink by -28.00% and then drop by -25.45% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 15.65%. While earnings are projected to return -31.19% in 2025, the next five years will return -1.73% per annum.
EYPT Dividends
EyePoint Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-May-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
EyePoint Pharmaceuticals Inc insiders own 3.54% of total outstanding shares while institutional holders control 109.29%, with the float percentage being 113.30%. CORMORANT ASSET MANAGEMENT, LP is the largest shareholder of the company, while 216.0 institutions own stock in it. As of 2024-06-30, the company held over 8.32 million shares (or 15.6467% of all shares), a total value of $72.43 million in shares.
The next largest institutional holding, with 5.18 million shares, is of SUVRETTA CAPITAL MANAGEMENT, LLC’s that is approximately 9.7279% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $45.03 million.
